Table of Contents

• Trial overview
• Prostate cancer studies
• Other cancers studied
• Study phases and participants
• Main endpoints and what they mean
• Safety and long-term follow-up

Trial overview

These studies investigate Lutetium (177Lu) Vipivotide Tetraxetan in people with different types of cancer, mostly prostate cancer.^[1] The trials are designed to check whether the treatment can improve cancer control, delay progression, and remain safe in different patient groups.^[2]

Prostate cancer studies

Most trials focus on prostate cancer, especially PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).^[3] Some studies look at earlier disease stages, including metastatic hormone-sensitive prostate cancer, oligometastatic prostate cancer, high-risk localized disease, locally advanced disease, and very high-risk prostate cancer.^[4]

Several phase 3 studies compare Lutetium (177Lu) Vipivotide Tetraxetan with standard care, observation, or a change in androgen receptor-directed therapy.^[5] These studies are trying to see whether the treatment can improve outcomes such as overall survival, radiographic progression-free survival, and metastasis-free survival.^[6]

Some prostate cancer trials test the treatment together with other medicines, such as androgen receptor pathway inhibitors or ipilimumab.^[7] Other studies look at re-treatment, neoadjuvant use before surgery, or use after radical treatment and hormone therapy.^[8]

Other cancers studied

Not all studies are in prostate cancer. One phase 2 trial studies clear cell renal cell carcinoma, and another phase 2 trial studies adenoid cystic carcinoma from the salivary glands.^[9] These studies help researchers learn whether the treatment may have a role in other PSMA-related or radiopharmaceutical research settings.^[10]

Study phases and participants

The trial list includes Phase 1, Phase 2, Phase 3, and one Phase IV post-authorization safety study.^[11] Early-phase studies usually focus on safety, tolerability, feasibility, and dosimetry, while later-phase studies focus more on effectiveness and long-term outcomes.^[12]

Participant groups vary by study. Some trials include adults with PSMA-positive disease, some require prior treatment exposure, and some focus on people with normal kidney function or renal impairment.^[13] A few trials include men who are candidates for radical prostatectomy, meaning surgery to remove the prostate gland.^[14]

Main endpoints and what they mean

The studies measure several main endpoints, which are the main results researchers want to learn about.^[15] Common endpoints include PSA50 rate, PSA response, objective response, biochemical failure, metastasis-free survival, radiographic progression-free survival, and overall survival.^[16]

PSA50 means a drop of at least 50% in prostate-specific antigen from baseline, which is the level before treatment starts.^[1] Objective response means a complete or partial shrinkage of cancer seen on imaging, and biochemical failure means the PSA level rises in a way that suggests the cancer is returning or worsening.^[17]

Some trials also measure dosimetry, which checks how radiation is distributed in the body, especially in organs such as the kidneys.^[12] Safety endpoints often count adverse events, serious adverse events, lab changes, dose interruptions, dose reductions, and treatment discontinuation.^[11]

Safety and long-term follow-up

Safety is a major part of the research program. One phase 4 study follows adult participants with prostate cancer for long-term safety after authorization, including selected adverse events and serious adverse events.^[11] The brief summary for this study says it is meant to further characterize long-term outcomes, including known or potential risks such as myelosuppression, renal failure, dry mouth, dry eyes, and secondary malignancies like myelodysplastic syndrome and acute myeloid leukemia.^[11]

Other trials also focus on tolerability, which means how well participants can stay on treatment without major dose changes or stopping early.^[7] This is important because several studies include repeated treatment cycles or combination treatment plans.^[1]